FLNA
FILANA THERAPEUTICS, INC.
Next earnings Aug 12, 2026 · consensus $-0.36 EPS
Last earnings -5.6% on 2026-05-07
$1.20
▲ +3.45%$1.20▼ -39.70%
over 1Y
L $1.16EODHDH $4.64
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.4%
1W-3.2%
1M-20.0%
3M-28.1%
YTD-42.6%
1Y-39.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Revenue grew 277.6% YoY; but unprofitable (net margin -221.2%).
FILANA THERAPEUTICS, INC. shows $41.1M in FY2013 revenue (+277.6% YoY), a -221.2% net margin, and -122.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$32.9M | -$80.0M | -$106M | -$141M | -$95.4M |
| Net income | -$32.4M | -$76.2M | -$97.2M | -$24.3M | -$91.0M |
| Diluted EPS | — | -$1.90 | -$2.32 | -$1.46 | -$1.88 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$37.5M
EV / EBITDA—
EV / Sales-0.9
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-156.9%
FCF yield-56.6%
Quality & risk
ROIC (est.)-101.3%
Free cash flow-$32.8M
Total debt—
Net cash$95.5M
Altman Z-Score-6.84 distress
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-112026-06-15open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗ARSPeriod ending 2025-12-312026-04-28open ↗DEF 14APeriod ending 2026-06-112026-04-28open ↗8-KPeriod ending 2026-04-222026-04-28open ↗10-KPeriod ending 2025-12-312026-03-12open ↗8-KPeriod ending 2026-03-122026-03-12open ↗8-KPeriod ending 2026-03-102026-03-10open ↗8-KPeriod ending 2026-02-192026-02-19open ↗8-KPeriod ending 2025-12-192025-12-23open ↗8-K/APeriod ending 2025-10-212025-12-22open ↗
Frequently asked
- Is FILANA THERAPEUTICS, INC. (FLNA) a buy?
- FLNA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 277.6% YoY; but unprofitable (net margin -221.2%).
- What is FILANA THERAPEUTICS, INC.'s quality score?
- FLNA scores 54.09803921568628/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001069530, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:59:09 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.